Aims: There are no treatments for the extreme hyperphagia and obesity in Prader-Willi syndrome (PWS). The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib. Results: One-hundred and seven participants were included in the intention-to-treat analysis: placebo (n = 34); 1.8 mg beloranib (n = 36); or 2.4 mg beloranib (n = 37). Improvement (reduction) in HQ-CT total score was greater in the 1.8 mg (mean difference −6.3, 95% CI −9.6 to −3.0; P = .0003) and 2.4 mg beloranib groups (−7.0, 95% CI −10.5 to −3.6; P = .0001) vs placebo. Compared with placebo, weight change was greater with 1.8 mg (mean difference − 8.2%, 95% CI −10.8 to −5.6; P < .0001) and 2.4 mg beloranib (−9.5%, 95% CI −12.1 to −6.8; P < .0001). Injection site bruising was the most frequent adverse event with beloranib. Dosing was stopped early due to an imbalance in venous thrombotic events in beloranib-treated participants (2 fatal events of pulmonary embolism and 2 events of deep vein thrombosis) compared with placebo.
| INTRODUCTION
Prader-Willi syndrome (PWS) is characterized by motor and cognitive delays, significant behavioural disturbances, low muscle tone, slow metabolism and extreme unrelenting hunger, resulting in hyperphagia and early childhood-onset obesity [1] [2] [3] that significantly contribute to morbidity and early mortality. [4] [5] [6] Without aggressive external control of eating behaviour, individuals with PWS develop severe obesity and are highly susceptible to obesity-related morbidities, including type 2 diabetes, obstructive sleep apnea and hypertension. 1, 7 Furthermore, obesity-related complications such as respiratory and cardiac failure, pulmonary embolism (a previously under-reported complication) and renal failure are leading causes of death in PWS, followed by deaths related to food seeking (gastrointestinal perforation, choking and accidents). 8 Moreover, the obsessive and compulsive behaviours displayed by individuals with PWS that are often directed toward obtaining and consuming food also have a profoundly deleterious impact on social function and quality of life. 9, 10 To our knowledge, there are no pharmacological treatment options for hyperphagia or obesity in PWS. Clinical experience with a variety of diets, supplements and other approaches has been disappointing, and the long-term risk-benefit of bariatric surgery [11] [12] [13] in PWS is unclear. The current management of hyperphagia and obesity in PWS focuses on lifelong food restriction, placing a substantial burden on individuals with PWS and their families. 9, 14, 15 Beloranib inhibits methionine aminopeptidase 2 (MetAP2), preventing removal of the proximal (amino-terminus) methionine residue from proteins cleaved by MetAP2. 16 Beloranib and other MetAP2 inhibitors reduce food intake, body weight, fat content and adipocyte size in animal models. [16] [17] [18] [19] [20] Weight loss caused by beloranib and other MetAP2 inhibitors is hypothesized to be due to direct effects on adipose tissue that reduce fat synthesis and increase fat oxidation as well as metabolic and hormonal changes that reduce appetite and food intake, while maintaining basal metabolic rate. 19, 21 In prior clinical trials in individuals with obesity (without PWS), beloranib produced clinically meaningful and sustained weight loss of 0.5 to 1.0 kg per week, and also reduced subject-reported hunger. 21, 22 Given the significant contribution of hyperphagic behaviours to obesity in PWS, the effect of beloranib on hyperphagia-related behaviours and body weight in PWS was tested in an unpublished randomized, placebo-controlled, proof-of-concept trial in 17 adults.
Beloranib treatment for up to 8 weeks reduced body weight, fat mass and plasma lipids, and attenuated hyperphagia-related behaviours.
The aim of the current clinical trial was to investigate the efficacy of beloranib in the treatment of hyperphagia and obesity as well as safety and tolerability over 26 weeks in adolescent and adult participants with PWS and co-morbid obesity.
| MATERIALS AND METHODS

| Study design and participants
The bestPWS study was a Phase III, randomized, placebo-controlled, 
| Randomization and masking
Participants were randomized via computer using a centralized Interactive and/or Web Response System (IxRS) in a 1:1:2:2 ratio to lower-dose placebo (0.45 mL), higher-dose placebo (0.6 mL), 1.8 mg beloranib (0.45 mL) or 2.4 mg beloranib (0.6 mL; Figure 1 in Appendix S1). Randomization was stratified based on recombinant human growth hormone use (yes/no) and age (≥16 years/<16 years). Pharmacy personnel not involved in the conduct of the study dispensed study medication in containers that differed only by participant code number. To ensure adequate blinding of the dosing volume (0.45 or 0.6 mL for 1.8 or 2.4 mg beloranib), syringes were supplied with a mark (no numbers or graduation) to indicate the appropriate dosing volume. Except for a Safety Review Committee that convened every 3 months to review safety and tolerability data, all participants and personnel remained blinded for the duration of the study. Maladaptive behaviour and quality of life were assessed using the Repetitive Behavior Scale-Revised (RBS-R) and Pediatric Quality of Life Inventory-Family Impact Module (PedsQL-FIM). HQ-CT responders were classified by a predefined anchor-based method utilizing the Caregiver Global Impression of Change (CGIC) question, where a score of "moderately better" was selected as a threshold for clinically meaningful change (questionnaire provided in Figure 2 , Appendix S1). The mean reduction in HQ-CT total score for all participants who were associated with a CGIC rating of moderately better was 7.7. Thus, HQ-CT responders were defined as those with a reduction in HQ-CT total score of at least 7.7.
| Procedures
Safety evaluations included assessment of incidence and severity of adverse events with onset on or after the first day of treatment, 
| Outcomes
The prespecified co-primary endpoints were the change in hyperphagia-related behaviours (indicated by HQ-CT total score) and the percent change in body weight from baseline to Week 26.
Hyperphagia-related behaviours were assessed by the HQ-CT, an instrument designed to measure symptoms of food-related preoccupations and behaviours that was completed by the caregiver; care- 
| Statistical analysis
We estimated that a sample size of 28 participants per group would provide 94% power to detect a between-group difference in each of the co-primary endpoints. To account for a dropout rate of up to 18%, the planned total sample size was 102 participants (34 per group). The power for the co-primary endpoints was calculated using a 2-sided, 2-sample t-test at a 5% significance level.
The pre-specified efficacy analyses used data from the intent-totreat population, which included all participants who underwent randomization, received at least one dose of study drug, and had baseline co-primary efficacy endpoint measurements. The safety analysis set included all participants who underwent randomization and received at least one dose of study drug. The co-primary and key secondary endpoints were analysed in a hierarchical order to control for overall type I error that first compared the 2.4 mg beloranib group with placebo at the 5% significance level, followed by the 1.8 mg beloranib
group. Both co-primary endpoints had to be statistically significant to deem the 2.4 mg beloranib dose superior to placebo. Unless described otherwise, efficacy endpoints were analysed separately using a mixed model for repeated measures (MMRM) with treatment group, growth hormone use, age (≥16 or <16 years), visit and treatment-by-visit interaction as fixed effects, the baseline value of the relevant variable as a co-variate, and participant as a random effect. Missing data were not imputed in the primary efficacy analyses that used a MMRM analysis. Sensitivity analyses were performed to assess the robustness of the primary efficacy analyses; analysis of covariance (ANCOVA) models were fit using various imputation strategies for missing data, including multiple imputation with retrieve dropouts, retrieve dropouts weighted analysis, baseline observation carried forward and last observation carried forward. Additionally, efficacy endpoints were evaluated for the per protocol population (all participants who received at least 67% of doses of study drug and who completed Week 26 without any notable protocol violations), and predefined subgroup analyses of the co-primary endpoints were conducted based on sex, baseline HQ-CT (dichotomized at median value), PWS genetic subtype, growth hormone use, BMI tertiles and age (≥16 or <16 years and ≥18 or <18 years). Adverse events were summarized by treatment group, system organ class and preferred term.
| RESULTS
Out of 126 screened individuals, 108 were randomized, and 107 received study drug and were included in the intent-to-treat and safety analysis populations ( Figure 1 , Appendix S1). Demographic and baseline characteristics were well matched across treatment groups for age, sex, growth hormone use, weight, BMI, fat mass and genetic a Data are mean (SD), n (%) or geometric mean (SE) for the safety population (N = 107). Percentages may not add up to 100 due to rounding.
b To account for skewness, data for triglycerides and hsCRP were log transformed, and values are geometric mean (SE).
subtype ( When the double-blind treatment was stopped, 74/107 (69%) participants had completed 26 weeks of treatment (placebo n = 24, 1.8 mg beloranib n = 26, 2.4 mg beloranib n = 24) and 6 participants had stopped treatment due to adverse events (placebo n = 0, 1.8 mg beloranib n = 4, 2.4 mg beloranib n = 2). The remaining 27 participants had completed at least 75% of the 26-week doubleblind treatment period and were not removed from the primary efficacy analysis. It was deemed that there were sufficient data to allow for a robust assessment of efficacy.
Beloranib resulted in statistically significant reductions from baseline to Week 26 compared with placebo for both co-primary endpoints ( Figures 1A and 2B ). After 26 weeks, the least-squares mean change in HQ-CT total score was −6.7 (SE 1.1) and −7.4
(1.3) in the 1.8 and 2.4 mg beloranib treatment groups, respectively, compared with −0.4 (1.2) in the placebo group, indicating a greater improvement in hyperphagia-related behaviours with beloranib treatment than placebo ( Figure 1A ; Table 2 ). The improvement in hyperphagia-related behaviours with beloranib was statistically significant compared with placebo at the earliest time point Change in co-primary endpoints and scatterplot of change in weight and Hyperphagia Questionnaire for Clinical trials (HQ-CT) total score. Least-squares mean change (SE) in HQ-CT total score (A) or least-squares mean percent change in body weight (B) from baseline to Week 26 for the intent-to-treat population. Estimated treatment differences are from a mixed model for repeated measures (MMRM) with no imputation for missing data. *P < .05, **P < .01, ***P < .001 for change from baseline for beloranib vs placebo. (C) Percent change in weight and absolute change in HQ-CT total score from baseline to Week 26 for each participant in the intent-to-treat population with missing data imputed using last observation carried forward measured (Week 4), and continued for the duration of treatment ( Figure 1A) .
The least-squares mean percent change in body weight from baseline to Week 26 was −4.1% (SE 0.9) and −5.3% (0.9) for the 1.8 Figure 1B ; Table 2 ). Consistent with the PWS phenotype and natural history, placebo-treated participants exhibited gradual weight gain, while beloranib-treated participants FIGURE 2 Change in Hyperphagia Questionnaire for Clinical trials (HQ-CT) individual item scores, participants with ≥5% weight loss, and change in body mass. A, Least-squares mean change (SE) in individual question scores for the HQ-CT at Week 26. Each item had 5 possible responses with a score ranging from 0 to 4 ( Figure 2, Appendix S1) . B, Percentage of participants categorized as body weight responders, i.e. with at least 5% weight loss. C, Least-squares mean change (SE) in body mass from baseline to Week 26 as measured by dual-energy absorptiometry (DXA). Data are for the intent-to-treat population. *P < .05, **P < .01, ***P < .001 for beloranib vs placebo exhibited weight loss that was statistically significant compared with placebo at the earliest time point measured (Week 4) and continued for the duration of treatment ( Figure 1B ).
The change in weight and HQ-CT total score for each participant is shown in Figure 1C . HQ-CT responders were classified by an anchor-based method in which a score of moderately better on the CGIC item was selected as a meaningful change; this corresponded to a mean reduction in HQ-CT total score of 7.7. Therefore, participants achieving a threshold reduction of ≥7.7 in HQ-CT total score were classified as responders.
Compared with 4/34 (12%) of placebo participants, 13/36 (36%) and 19/37 (51%) of participants in the 1.8 and 2.4 mg beloranib groups, respectively, were classified as HQ-CT responders (P = .0175 and P = .0005; Figure 6B , Appendix S1).
No placebo-treated participants had weight loss of at least 5%; however, 13/36 (36%) and 19/37 (51%) of participants in the 1.8 and 2.4 mg beloranib treatment groups achieved this benchmark (P = .0001 and P < .0001; Figure 2B ). Almost all weight loss was attributed to a reduction in fat mass ( Figure 2C ). Placebo-treated participants gained 2.6 kg fat mass at Week 26, while 1.8 and 2.4 mg beloranib-treated participants had a mean change in fat mass of −2.5 and −5.0 kg, respectively and a small change in lean mass that was not statistically significant. In beloranib-treated participants, fat mass accounted for approximately 85% of weight loss.
Baseline lipids were generally within normal limits (Table 1) .
Beloranib-treated participants had substantial and statistically significant reductions in LDL cholesterol that contributed to the reduction a Data are least-squares mean (SE) and 95% confidence interval, for change from baseline to Week 26 for the intent-to-treat population.
b Estimated treatment differences are from a MMRM with no imputation for missing data. To account for skewness, data for triglycerides and hsCRP were log-transformed for analysis, and treatment effects are presented as relative to baseline (ratio of Week 26 to baseline value).
c Values are geometric least-squares means (SE) for change from baseline to Week 26, and treatment effect refers to the ratio of the baseline and Week 26 geometric least-squares means.
in total cholesterol (Table 2 ). There were no significant changes in HDL cholesterol or triglycerides. hsCRP was reduced with both doses of beloranib compared with placebo (Table 2 ). Both doses of beloranib were also associated with statistically significant salutary changes in the adipokines, leptin and adiponectin (Table 2) .
Adverse events were more common among beloranib-treated participants compared with placebo during the 26-week randomized treatment phase (Table 3) . Most were mild to moderate in severity.
The most frequent adverse event in beloranib-treated participants was injection site bruising (Table 3 ). All injection site-related adverse events were mild, except for one moderate adverse event of injection site pain (in a participant in the 2.4 mg beloranib group) that resulted in withdrawal of study drug. Six beloranib and no placebo participants Aggression, anxiety and irritability were the most commonly reported psychiatric adverse events (Table 3) . Of these, anxiety and irritability were more frequent with beloranib than placebo. Most of these adverse events occurred in participants with a relevant medical history. Vital signs were generally unchanged in all treatment groups, and there were no notable safety signals or laboratory findings.
| DISCUSSION
The bestPWS trial is the first large randomized clinical trial to demonstrate statistically significant and clinically meaningful improvements in hyperphagia-related behaviours and weight loss in individuals with PWS. In this population, the only effective treatment options currently available involve continuous restriction of access to food that is typically combined with a rigorous exercise routine. Data are n (%) or number of participants (%)/number of events.
a Adverse events that occurred from baseline to Week 26 in the safety population (N = 107). Adverse events are included if they had an onset date on or after the first dose of study drug.
obesity in PWS can be successfully treated with a pharmacological approach.
Although other pharmacological approaches to the management of weight and hyperphagia in individuals with PWS have been investigated, 23, 24 none has been effective in reducing hyperphagia.
Only growth hormone has been shown to produce a moderate improvement in weight and body composition in some patients. 25 Extant behavioural treatments for obesity in individuals with PWS fail to address the extreme hunger and food-seeking drive these individuals experience, and instead rely on reducing energy intake by limiting access to food. 9, 14, 15 This places a substantial burden on families and caretakers, and causes most adult individuals with PWS to live in group homes with a strictly controlled environment. Participants in the placebo group experienced weight gain (especially adolescent participants) over the 26-week study, while those treated with beloranib had weight loss that continued for the duration of the study. Consistent with the participant population, participants had very high fat mass at baseline (approximately 50%), 26 and weight loss was mostly due to loss of body fat. There were also improvements in obesity-related markers of metabolic and cardiovascular risk, including hsCRP. CRP is elevated in a wide range of acute and chronic inflammatory conditions, and is an independent predictor of coronary events and stroke in adults. 27 Consistent with previous observations in participants with PWS, 28,29 mean hsCRP concentrations were elevated at baseline (>3 μg/mL).
Beloranib-treated participants exhibited statistically significant changes in the adipokines, adiponectin and leptin, compared with placebo. These changes are in keeping with the hypothesized effects of beloranib on adipose tissue. Adiponectin is normally abundant, but concentrations are reduced in obesity, diabetes and cardiovascular disease as well as in adults (but not children) with PWS. 26, 30, 31 Circulating leptin concentrations are correlated with adiposity, and participants with PWS have elevated leptin, consistent with increased fat mass. [31] [32] [33] The reduction in leptin and increase in adiponectin observed with beloranib treatment are consistent with weight loss and the concomitant decrease in fat mass. 34 The mechanisms for weight loss and improvement in cardiometabolic markers with MetAP2 inhibitors are attributed to 2 primary effects: increased fat mobilization and oxidation; and decreased caloric intake. 17, 18, 22 Although the specific mechanisms that produce these effects continue to be investigated, increased stability of
MetAP2 is expected to attenuate activity of extracellular signalregulated kinases 1 and 2 (ERK1/2), resulting in a cascade of downstream effects. 35 Some of these effects include suppression of sterol regulatory element binding protein (SREBP) activity resulting in reduced lipid and cholesterol biosynthesis, 36, 37 and effects on other signalling cascades, including retinoic acid-related orphan receptor α (RORα), which is implicated in fat biosynthesis, insulin action and inflammation. 38 Reductions in hunger and caloric intake are likely the result of an integrated effect of changes in circulating fatty acids, lipids, adipokines and other peripheral signals on CNS regions that regulate appetite. 39 Whether MetAP2 inhibition normalizes the hyperactivation evident in brain regions that drive eating behaviour that has been observed in patients with PWS remains to be determined. 40 Beloranib has been studied in individuals with obesity, type 2 diabetes and hypothalamic injury-associated obesity. that contributes to these events. Preliminary results lead us to postulate that beloranib slows endothelial cell proliferation, which influences pro-and anticoagulant factors on the cell surface. 41 This effect is expected to be exacerbated by the extended exposure produced by the suspension formulation, which results in drug exposure lasting at least 12 hours after each dose, and is hypothesized to contribute to the imbalance of thrombotic events in clinical trials of beloranib.
Compared with placebo, beloranib was associated with a greater number of adverse events of anxiety and irritability. These types of psychiatric disorders are common in PWS, 15 and most of these events occurred in individuals with a relevant medical history. The mechanisms through which beloranib might increase the prevalence of such events is unclear.
The major study limitation was the early halting of the trial. Not all participants received 26 weeks of treatment, though the majority completed the trial and those that did not complete the trial completed at least 75% of the treatment period. Nevertheless, the effect size was large enough that robust statistical significance could be ascertained even with early halting of the study. Additionally, the low number of participants with PWS and diabetes did not allow for a separate assessment of an effect of beloranib on glycaemic control in these participants.
The bestPWS clinical trial is the first study to demonstrate that treatment with a pharmacological agent can reduce the pathological hunger experienced by participants with PWS and produce clinically meaningful weight loss. The mechanism for weight loss is currently under investigation, but appears to be due to reduced energy intake (due to reduced hyperphagia) as well as reduced adipocyte mass and improved adipocyte function. Beloranib is no longer being investigated as a potential treatment for hyperphagia and obesity in PWS due to the occurrence of serious venous thrombotic events. However, alternative MetAP2 inhibitors without an effect on thrombotic parameters, as well as the proteins whose actions are altered by MetAP2 inhibition offer promising targets for treating the hyperphagia and obesity in PWS.
